A Case of Relapsing-Remitting Neuroborreliosis? Challenges in the Differential Diagnosis of Recurrent Myelitis by Albrecht, P. et al.
 
Case Rep Neurol 2012;4:47–53 
DOI: 10.1159/000337223 
Published online: 
March 14, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable 
to the online version of the article only. Distribution for non-commercial purposes only.   
 
                      P. Albrecht    Department of Neurology, Medical Faculty 
Heinrich Heine University Düsseldorf, Moorenstrasse 5 
DE–40225 Düsseldorf (Germany) 
Tel. +49 211 811 7880, E-Mail phil.albrecht @ gmail.com 
 
47 
   
A Case of Relapsing-Remitting 
Neuroborreliosis? Challenges 
in the Differential Diagnosis of 
Recurrent Myelitis 
P. Albrecht
a    N. Henke
a    H.C. Lehmann
a    S. Macht
b    
H. Hefter
a    N. Goebels
a    C. Mackenzie
c    T.A. Rupprecht
d    
V. Fingerle
e    H.P. Hartung
a    A. Methner
a  
Departments of 
aNeurology, 
bDiagnostics and Interventional Radiology, and 
cMedical Microbiology and Hospital Hygiene, Medical Faculty, Heinrich Heine 
University, Düsseldorf, 
dDepartment of Neurology, Amper Clinic Dachau, 
Dachau, and 
eNational Reference Center for Borrelia and Ehrlichia, Bayerisches 
Landesamt für Gesundheit und Lebensmittelsicherheit, Oberschleissheim, 
Germany 
 
 
Key Words 
Neuroborreliosis · Borrelia burgdorferi · Lyme borreliosis · Cerebrospinal fluid ·  
Myelitis · CXCL13 
 
 
Abstract 
We report the case of a 31-year-old woman with 4 episodes of myelitis with pleocytosis, a 
positive Borrelia burgdorferi serology with positive antibody indices, and full recovery each 
time after antibiotic and steroid treatment, suggesting neuroborreliosis. We nevertheless 
believe that recurrent neuroborreliosis is improbable based on the levels of the chemokine 
CXCL13 in cerebrospinal fluid and favor the diagnosis of post-infectious autoimmune-
mediated transverse myelitis possibly triggered by an initial neuroborreliosis as the cause of 
the relapses observed in our patient. We demonstrate the diagnostic steps and procedures 
which were important in the differential diagnosis of this unusual and challenging case. 
 
Introduction 
Lyme borreliosis is a tick-borne anthropozoonosis caused by the spirochete Borrelia 
burgdorferi. Asymptomatic infections are frequent in Europe, as Borrelia-specific 
antibodies have been observed in 5–25% of healthy subjects [1–4]. The primary stage 
is characterized by erythema migrans and can be followed by dissemination of disease,  
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which mainly affects the joints, heart or nervous system [4–6], within weeks to months. 
The most frequent neurological manifestation of Lyme borreliosis is 
meningopolyradiculoneuritis. Neuroborreliosis of the central nervous system (CNS) is 
rare, and differentiation from other disorders of the CNS with concomitant 
seropositivity for B. burgdorferi can be difficult. 
Herein, we report a case with positive B. burgdorferi serology and 4 episodes of 
severe CNS manifestations with full recovery each time after sufficient antibiotic 
treatment. We illustrate the diagnostic steps and procedures which were valuable for 
posing the differential diagnosis in this unusual case, taking into account current state-
of-the-art procedures for the diagnosis of Lyme borreliosis. 
Case History 
A 31-year-old woman presented with a 2-day history of rapidly progressing hypoesthesia of the 
body below the neck, tetraparesis, gait ataxia, brainstem symptoms, and urinary retention. 
This was already the fourth episode of symmetric sensomotoric deficits of the limbs. Fifteen years 
earlier, in 1996, she had suffered from a mild paraparesis with hypoesthesia of both legs, which 
remitted completely after treatment with an oral antibiotic and glucocorticoids. Details were not 
remembered and neither cerebrospinal fluid (CSF) analysis nor MRI scans had been performed. 
The second episode occurred 3 years later, in 1999, with acute urinary retention and a mild-to-
moderate sensomotoric deficit below dermatome T6. Transcranial magnetic motor evoked potentials 
(MEP) and somatosensory evoked potentials (SSEP) were altered. Cerebral and spinal MRI scans were 
normal, but CSF analysis showed a lymphocytic pleocytosis of 260 leukocytes/μl, and a highly 
elevated B. burgdorferi CSF/serum IgG antibody index (AI) of 8.0 (normal <2.0), leading to the 
diagnosis of neuroborreliosis with transverse myelitis. The patient was subsequently treated 
intravenously for 14 days with ceftriaxone 2 g/day and prednisolone 80 mg/day and recovered 
completely. Control CSF analysis showed a regression of the pleocytosis to 30 leukocytes/µl and a 
reestablishment of the blood-brain barrier (BBB) function with an albumin CSF/serum quotient of 3.6 
compared to 12.8 before treatment. 
During the third episode in 2008, the patient developed neck pain, a mild gait ataxia, and 
paresthesia of both legs. Cerebral and spinal MRI scans, MEP and SSEP were normal, but CSF analysis 
revealed 293 leukocytes/µl with a positive B. burgdorferi IgM (EIA and Western blot) in serum but not 
in CSF. The AI was reported to be normal. Treatment consisted of intravenous ceftriaxone 2 g/day, 
which was later switched to oral doxycycline 100 mg bid and notably no corticosteroids. The patient 
made a complete clinical recovery, and CSF reanalysis after treatment showed a reduction of the 
pleocytosis to 15 leukocytes/µl. 
The only other remarkable prior condition was an X-type histiocytosis with a strictly dermal 
manifestation diagnosed in 1982, which completely remitted and had not caused any further 
manifestation since treatment with methotrexate and Purinethol. Notably, the patient did not recall a 
tick bite or erythema migrans at any time. 
Neurological Symptoms and Diagnostic Findings on Admission 
On admission in March 2011, the patient presented with a sustained gaze-evoked nystagmus to the 
left and an incomplete abducens nerve paralysis. Motor examination revealed a moderate-to-severe 
symmetric tetraparesis. Reflexes were brisk in all extremities and the plantar response was neutral. 
The patient was not able to stand or walk, but showed moderate ataxia of all limbs. Sensory testing 
revealed sensory deficits below dermatome C4, with impaired discrimination of sharp and dull, and 
essentially no sense of vibration, temperature and position. She complained of urinary retention. 
A spinal MRI scan revealed extensive signal alterations especially in the cervical, but also in the 
thoracic spinal cord. Some of these lesions comprised 2 or more segments and involved large parts of 
the cord’s cross section (fig. 1a, b), in combination with moderate swelling at the cervical level and a  
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faint enhancement after intravenous gadolinium administration (not shown). A cerebral MRI scan 
showed bilateral pontine T2 signal hyperintensities (fig. 1c). 
CSF analysis revealed a predominantly lymphocytic pleocytosis of 136 leukocytes/µl; dysfunction 
of the blood-CSF barrier, with an elevated CSF/serum albumin quotient of 18.8; and an elevated total 
CSF protein of 126 mg/dl. There were no oligoclonal bands, but a Reiber diagram suggested 
intrathecal synthesis of IgM (IgM quotient 11.96, IgM index 0.64) but not IgG (IgG quotient 12.78, IgG 
index 0.68). Measles, rubella, and zoster AIs (MRZ reaction <1.3) were negative. CSF/serum AIs of 
52.6 and 18.8 were highly positive for B. burgdorferi IgM and IgG, respectively, with a B. burgdorferi-
specific IgM concentration of 18.9 U/ml and an IgG concentration of 1.3 U/ml in CSF. Western blotting 
was positive in CSF and serum for p41- and OspC-specific IgM and IgG at day 1, and revealed an 
additional positive Osp17-IgM band in serum at days 7 and 17 (fig. 1d). Quantitative real-time PCRs 
amplifying the OspA gene and the P41 gene of B. burgdorferi sensu lato were negative in CSF. The 
workup was extended and included other differential diagnoses. Serology for Mycoplasma 
pneumoniae was positive in serum (immunohistochemical assay, 1:320; enzyme immunoassay, 
borderline positive) but not in CSF. Two different PCRs for detection of mycoplasma DNA were 
performed on CSF. A specific PCR for M. pneumoniae was negative. A PCR for 16S ribosomal DNA was 
positive, and the amplicon was cloned and sequenced but revealed no mycoplasma-specific 
sequences. Primer sequences can be obtained from the authors. 
Four months after the episode, serological controls revealed a non-significant rise in M. 
pneumoniae titer in serum (immunohistochemical assay 1:640), with persistent negative results in 
CSF. Aquaporin-4 antibodies were negative, as were antinuclear antibodies, antineutrophil 
cytoplasmic antibodies, anti-DNA antibodies, anti-extractable nuclear antigens, HIV-, Treponema-, 
hepatitis B and C serology, and PCR of HSV, CMV, VZV and EBV in the CSF. Angiotensin converting 
enzyme activity in serum was normal. 
The evoked potentials gave evidence of an affection of the central pyramidal tract and a 
demyelinating affection of the somatosensory afferents in both legs, while visual and acoustic evoked 
potentials were normal. Electroneurography excluded an involvement of the peripheral nervous 
system. 
Treatment and Course of Recovery 
The patient was treated with intravenous ceftriaxone 2 g/day, acyclovir 3 × 750 mg/day and 
methylprednisolone 1 g/day. Acyclovir was discontinued after a negative PCR for HSV and VZV DNA. 
Ceftriaxone was continued for 21 days. After 1 week, methylprednisolone was continued orally and 
tapered out over 2 weeks. The patient’s clinical status ameliorated rapidly; she started to walk again 
after 1 week and was out of bed most of the day after 3 weeks. 
CSF analysis after 7 days of treatment revealed a reduction of leukocytes to 26/µl along with a 
reduction of the total protein to 33 mg/dl and a reconstitution of the blood-CSF barrier. Pleocytosis 
dropped further after 10 more days to 18/µl. Cytological examination of all 3 spinal CSF samples 
showed lymphocytic pleocytosis but no lymphoblasts or other atypical cells. The CSF/serum AI 
decreased after 7 days of treatment to 34.1 for IgM and 12.7 for IgG, and after a further 10 days to 
17.4 for IgM and 15.6 for IgG. AIs were negative for Borrelia-specific IgG and further decreased for 
IgM (IgG negative in serum and CSF, IgM AI 6.5) after 4 months. The levels of CXCL13 were only 
slightly elevated in CSF and did not rise in the course of the current episode (35 pg/ml at onset, 4.2 
pg/ml after 7 days, 4.5 pg/ml after another 10 days and 4.5 pg/ml after 4 months), which argues 
against acute neuroborreliosis during this episode. Pathological MEP became normal again after 20 
days of treatment. 
Discussion 
The differential diagnostic for the relapsing spinal syndromes of our patient 
comprises spinal lymphoma, a spinal manifestation of X-type histiocytosis, 
neuromyelitis optica, multiple sclerosis (MS) or a systemic autoimmune disease. As our 
patient presented with only spinal and brainstem symptoms and no supratentorial 
lesions were detectable in MRI, the diagnostic criteria for MS were not fulfilled [7]. The  
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long asymptomatic course between relapses, the absence of atypical cells in CSF, the 
positive response to antibiotic treatment (even without corticosteroids in 2008) and 
the serological findings argue against lymphoma. A relapse of X-type histiocytosis after 
14 years without symptoms seems very improbable as the microscopic analysis of CSF 
revealed no evidence of histiocytes, and myelitis as a manifestation of histiocytosis is 
an extremely rare event, even though it has been previously reported [8]. The severe 
pleocytosis and damage to the BBB argue against neuromyelitis optica, MS or vasculitis 
especially since the visual system was unaffected and aquaporin-4 antibodies, 
oligoclonal bands, MRZ reaction, supratentorial MRI and the laboratory screening for 
vasculitis were negative. 
The fact that a positive B. burgdorferi CSF/serum AI was found in 3 out of 4 episodes 
and that CSF pleocytosis and clinical symptoms ameliorated in response to antibiotic 
treatment seems to suggest recurrent episodes of neuroborreliosis. However, recurrent 
episodes of borreliosis and even more so neuroborreliosis after sufficient antibiotic 
treatment such as in this case, are very uncommon. If relapses occur, they are 
attributed to reinfections or relapses after inadequate antibiotic therapy. Moreover, it 
needs to be considered that the patient did not recall any previous tick bite or erythema 
migrans nor does she belong to a part of the population with an increased risk for 
repeated tick bites. Further, it remains unclear why the AI was negative during the 
third episode while all other signs and symptoms were similar. All 4 episodes 
manifested with a spinal syndrome despite the fact that B. burgdorferi myelitis 
represents less than 5% of cases with neuroborreliosis in larger studies [9–11]. 
Positive CSF/serum IgG AI can be found after a successfully treated and no longer 
active neuroborreliosis. But we would expect continuously positive predominantly IgG 
AIs in the case of AI persistence after an acute infection or during a persisting or 
remitting infection involving the CNS. However, this was not the case during the 
episode in 2008 when the AI was normal or in the current episode when AIs returned 
to normal 3 months after the start of the episode. 
AIs can change over time depending on the activation status of the immune system. 
Increasing AIs are not specific for an acute borreliosis as they can also be the result of 
an unspecific stimulation of the immune system, e.g. by an autoimmune manifestation 
or a yet unidentified infection in our patient. AIs are calculated as the ratio of specific to 
total immunoglobulins in CSF divided by the ratio of specific to total immunoglobulins 
in serum. It is therefore possible that low concentrations of total immunoglobulins in 
CSF give rise to positive AIs at rather low specific concentrations in CSF, like the 
Borrelia-specific IgG concentration of 1.3 U/ml observed in our patient. In line with 
this, a Reiber diagram gave no evidence of intrathecal IgG synthesis in our patient. 
Therefore, further parameters were needed to resolve the diagnostic dilemma in this 
case. Real-time PCR-based results for B. burgdorferi in CSF are often negative, as are 
cultures, even in the case of active neuroborreliosis; however, positive results can serve 
to ascertain the diagnosis. Thus, negative PCR results do not exclude neuroborreliosis 
in this case. 
The level of CXCL13 in CSF is a very sensitive parameter for neuroborreliosis and 
can be of great help, especially in complex cases like ours [12, 13]. In several studies 
using the same ready-made ELISA from R&D Systems as in our patient, untreated 
neuroborreliosis could be differentiated from other neurological disorders with a high  
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sensitivity of above 90% using cutoff values of CXCL13 concentrations in CSF of 250 
pg/ml [14], 100 pg/ml [15] or 142 pg/ml [16]. In a prospective trial, where a self-made 
ELISA with different binding properties was used, a sensitivity of 94.1% and a 
specificity of 96.1% were obtained with a cutoff of 1,229 pg/ml, and sensitivity even 
reached 100% at a cutoff of 697 pg/ml [12]. An important finding of this large trial was 
that the CXCL13 concentration in CSF could discriminate neuroborreliosis from MS. The 
CXCL13 levels found in MS were only moderately elevated, like in our case. A reanalysis 
of the data of this prospective study revealed a negative predictive value of 99% for 
acute untreated neuroborreliosis (A. Plate, pers. commun.). 
This large body of evidence clearly indicates a good negative predictive value for the 
CXCL13 concentration of 35 pg/ml observed in our patient. Thus, the recurrence of 
episodes despite sufficient antibiotic therapy and the fact that she did not recall a tick 
bite or erythema migrans and did not belong to a risk group for repeated tick bites 
strongly argue against acute neuroborreliosis as the cause of our patient’s current 
episode. 
Instead, it seems most probable that our patient had suffered from neuroborreliosis 
in the past, e.g. when she had her first episodes of neurological symptoms in 1996 
and/or 1999, which was effectively treated and cured back then. We interpret the 
subsequent episodes in 2008 and 2011 as post-infectious autoimmune-mediated 
transverse myelitis triggered by the preceding neuroborreliosis. Immune responses 
specific against CNS proteins or myelin have been reported in CSF of neuroborreliosis 
patients [17–22], and post-infectious autoimmune mechanisms following Lyme 
borreliosis have been discussed for arthritis and autoimmune polyneuropathy [23, 24]. 
So an autoimmune mechanism caused by molecular mimicry seems a plausible 
explanation for the relapsing events of myelitis observed in our patient. The fact that 
she recovered in 2008 even without steroid treatment does not argue against an 
autoimmune transverse myelitis, as these disorders are also known to show 
spontaneous remissions, albeit with a slower recovery than with steroid treatment. 
Also, the fact that we did not observe more bands in the B. burgdorferi Western blot in 
CSF and serum argues against a persistent and relapsing neuroborreliosis, in which we 
would expect more bands, particularly IgG. The findings are in line with our assumption 
that our patient had contact with B. burgdorferi before, possibly even neuroborreliosis 
during one of the first episodes. Thus, the bands detectable in CSF and serum during the 
fourth episode would have been caused by a persistence of specific B cells, which are 
stimulated in the context of the presumed autoimmune event. 
Taken together, our case highlights the diagnostic challenges that may occur in 
patients with inflammatory lesions of the spinal cord and/or positive B. burgdorferi 
serology. 
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Fig. 1. Extensive high-signal alterations are visible in the cervical and thoracic spinal cord, 
comprising large portions of the medullar cross section (sagittal STIR, short-tau inversion recovery 
sequence, a; axial T2-weighted turbo spin echo sequence, b). c Cerebral involvement is also seen as 
bilateral hyperintense signal alterations in the dorsal portions of the pons (axial T2-weighted turbo 
spin echo sequence). d Western blots for IgG and IgM of serum and CSF at day 1 (d1) and serum at 
day 7 (d7) and day 17 (d17). Bands before the blue alignment marker are positive controls for 
serum, IgG, IgM and a cutoff control (in this order). The Borrelia-specific antigens p41, OspC, and 
Osp17 are indicated. The VlsE antigen showed no band in any of the samples. 
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